礼来2025H1营收增长41%,制药收入跻身全球前5→

谈思生物
Aug 09

2025.08.09本文字数:1040,阅读时长大约2.6分钟导读:礼来2025上半年狂揽283亿美元,GLP-1双子星冲刺药王;全年预期再拔高至620亿,并购+BD豪掷近百亿。7日,礼来公布2025年上半财年成绩单:六个月累计收入282.862亿美元,同比增幅达41%。就目前已经交出考卷的跨国药企而言,礼来按整体销售额排在第6位,而仅看制药板块则升至第4,其座次与去年同期相比出现显著波动。全球...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10